Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTS Intratumoral Injection in Advanced Solid Tumors
NCT03448211Phase 1Withdrawn
- Sponsor
- PTS International
- Start
- May 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of para-toluenesulfonamide in solid tumor, breast cancer, lung cancer and 1 more, sponsored by PTS International. Primary endpoint: Maximum Tolerable Dose. Planned start May 2018; status: withdrawn.
02
Drugs
para-toluenesulfonamide
03
Conditions
solid tumorbreast cancerlung cancerAirway obstruction
Beyond the preview
Go deeper on NCT03448211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03448211.